Physician profile

Annabelle Razon

Family Medicine · San Diego, CA

NPI 1649301946

$610.86

in general payments reported to CMS, 2019-2025

8 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$39.92

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Janssen Pharmaceuticals, INC $238.37 2019-2022
Bayer Healthcare Pharmaceuticals INC. $158.21 2022
Sanofi-Aventis U.S. LLC $81.28 2019-2022
Scilex Pharmaceuticals INC. $42.43 2019
Cardiva Medical, INC. $39.92 2023 Cardiva Vascade 6/7f Vcs
Amarin Pharma, INC. $18.23 2021
Sunovion Pharmaceuticals INC. $18.02 2021
Astrazeneca Pharmaceuticals LP $14.40 2019

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Annabelle Razon

$610.86

in general payments reported 2019-2025

Years
2019-2023
Top company
Janssen Pharmaceuticals, INC

https://glasscript.com/doctor/210775/annabelle-razon

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.